

Clinical Updates from San Antonio
Clinical Update #3: HER2+ and HER2-low Breast Cancer

References

Tweet 2

Cortes J, Kim SB, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. *N Engl J Med*. 2022;386(12):1143-1154. doi:10.1056/NEJMoa2115022

Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2017;18(6):732-742. doi:10.1016/s1470-2045(17)30312-1

Hurvitz S, Hegg R, Chung W-P, et al. GS2-02 Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated survival results of the randomized, phase 3 study DESTINY-Breast03. Presented at: SABCS; December 7, 2022; San Antonio, TX. Accessed December 1, 2022.

Hurvitz SA, Hegg R, Chung W-P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. *Lancet*. 2022. doi:10.1016/s0140-6736(22)02420-5

Krop I, Park Y, Kim S-B, et al. GS2-01 Trastuzumab deruxtecan vs physician's choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02. Presented at: SABCS; December 7, 2022; San Antonio, TX. Accessed December 1, 2022.

Modi S, Saura C, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. *N Engl J Med*. 2020;382(7):610-621. doi:10.1056/NEJMoa1914510

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Breast Cancer (v4.2022). Updated June 21, 2022. Accessed August 1, 2022. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. *N Engl J Med*. 2012;367(19):1783-1791. doi:10.1056/nejmoa1209124

Glossary

2L, second line

3L, third line

4L, fourth line

aBC, advanced breast cancer

AE, adverse event

AST, aspartate aminotransferase

BC, breast cancer

CI, confidence interval
DB02, DESTINY-Breast02
DB03, DESTINY-Breast03
HER2, human epidermal growth factor receptor 2
IHC, immunohistochemistry
mBC, metastatic breast cancer
mOS, median overall survival
mPFS, median progression-free survival
NE, not estimable
NR, not reached
ORR, objective response rate
OS, overall survival
Ph3, phase 3
T-DM1, trastuzumab emtansine
T-DXd, trastuzumab deruxtecan
w/, with